Skip to main content
. 2020 Aug 28;13(12):100856. doi: 10.1016/j.tranon.2020.100856

Fig. 3.

Fig. 3

Engineering monoclonal cell lines expressing mutant KRAS and measuring change in antitumor response with variation in epitope frequency, a) Sanger sequencing results confirm expression of the D153S mutation alongside WT allele – in a monoclonal cell line to be referred as 3F11, b) Effect of mutation on orthotopic pancreatic tumor growth via bioluminescence imaging (n = 4–10). Day 10 post tumor inoculation, KPCF1 is a KPC cell line with KRASG12D mutation, 3F11 is a KPC cell line with KRASG12D/D153S mutation, c) Imaging protocol for panels b and e. BLI stands for Bioluminescence imaging, and D stands for Day, d) Sanger sequencing results confirm expression of the D153M mutation alongside WT allele – in a monoclonal cell line to be referred as 4E1, e) Effect of mutation on orthotopic pancreatic tumor growth via bioluminescence imaging (n = 4–5). Day 10 post tumor inoculation, KPCF1 is a KPC cell line with KRASG12D mutation, 4E1 is a KPC cell line with KRASG12D/D153M mutation. Data show mean ± SEM. * p < .05, ** p < .01, *** p < .001, **** p < .0001.